Topical Diacerein in Psoriasis Vulgaris
ConditionPsoriasis Vulgaris
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorCairo University
About this trial
The goal of this clinical trial is to evaluate the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris. The primary objective of the study is to compare the proportion of participants who achieve a clinically meaningful improvement in disease severity between the topical diacerein group and the placebo group.
Participants will:
Be assigned to receive topical diacerein 1% or placebo twice daily for a treatment period of 2 months.
Attend follow-up visits at Weeks 2, 4, 6, and 8. Undergo an additional evaluation one month after treatment cessation.
Eligibility criteria
Qualifiers
Age ≥18 years old of both genders.
Patients with mild chronic plaque psoriasis body surface area (BSA < 10%) along with Psoriasis Area and Severity Index (PASI) score of < 10, and/or Dermatology Life Quality Index (DLQI) score of <10.
Disqualifiers
Documented hypersensitivity or idiosyncratic reaction to the investigational product or any excipients contained within the cream formulation.
Intake of anti-psoriatic systemic therapy within the last 3 months, or topical treatments within the last 2 weeks.
Patients with pustular psoriasis.
Pregnant and breast-feeding individuals.
Trial design
Treatments tested in this trial
- Diacerein
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov